Cue Biopharma, Inc. (CUE)
28.74
+0.74
(+2.64%)
USD |
NASDAQ |
Sep 11, 16:00
28.83
+0.09
(+0.31%)
Pre-Market: 20:00
Cue Biopharma Enterprise Value : 141.71M for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 141.71M |
| September 10, 2026 | 137.84M |
| September 09, 2026 | 150.91M |
| September 08, 2026 | 148.30M |
| September 04, 2026 | 134.91M |
| September 03, 2026 | 136.11M |
| September 02, 2026 | 132.40M |
| September 01, 2026 | 140.14M |
| August 31, 2026 | 124.87M |
| August 28, 2026 | 137.21M |
| August 27, 2026 | 138.67M |
| August 26, 2026 | 142.28M |
| August 25, 2026 | 131.35M |
| August 24, 2026 | 112.63M |
| August 21, 2026 | 116.82M |
| August 20, 2026 | 120.11M |
| August 19, 2026 | 128.84M |
| August 18, 2026 | 125.81M |
| August 17, 2026 | 135.96M |
| August 14, 2026 | 170.26M |
| August 13, 2026 | 153.94M |
| August 12, 2026 | 150.49M |
| August 11, 2026 | 139.09M |
| August 10, 2026 | 127.90M |
| August 07, 2026 | 133.24M |
| Date | Value |
|---|---|
| August 06, 2026 | 132.66M |
| August 05, 2026 | 130.78M |
| August 04, 2026 | 130.52M |
| August 03, 2026 | 131.93M |
| July 31, 2026 | 131.77M |
| July 30, 2026 | 150.39M |
| July 29, 2026 | 137.89M |
| July 28, 2026 | 149.60M |
| July 27, 2026 | 161.74M |
| July 24, 2026 | 159.38M |
| July 23, 2026 | 164.46M |
| July 22, 2026 | 170.26M |
| July 21, 2026 | 166.39M |
| July 20, 2026 | 153.26M |
| July 17, 2026 | 154.36M |
| July 16, 2026 | 136.74M |
| July 15, 2026 | 140.40M |
| July 14, 2026 | 154.99M |
| July 13, 2026 | 153.11M |
| July 10, 2026 | 183.75M |
| July 09, 2026 | 182.34M |
| July 08, 2026 | 176.27M |
| July 07, 2026 | 166.02M |
| July 06, 2026 | 161.34M |
| July 02, 2026 | 139.20M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Nurix Therapeutics, Inc. | 2.218B |
| Monte Rosa Therapeutics, Inc. | 616.02M |
| Xilio Therapeutics, Inc. | -70.98M |
| ACADIA Pharmaceuticals, Inc. | 3.908B |
| Alnylam Pharmaceuticals, Inc. | 32.94B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -153.07M |
| Revenue (Quarterly) | 7.877M |
| Total Expenses (Quarterly) | 160.94M |
| EPS Diluted (Quarterly) | -24.14 |
| Gross Profit Margin (Quarterly) | 99.54% |
| Profit Margin (Quarterly) | -1.94K% |
| Earnings Yield | -93.95% |
| Normalized Earnings Yield | -103.36 |